Active Liver Cancer Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Liver Cancer Clinical Trial?

• Find Trials That Fit — Browse recruiting Liver Cancer trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Liver Cancer type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Liver Cancer Clinical Trial FAQ

What liver cancer treatments are currently in clinical trials?

Active trials are testing combination immunotherapy (atezolizumab + bevacizumab variants, nivolumab + ipilimumab, tremelimumab + durvalumab), novel checkpoint inhibitors targeting LAG-3 and TIGIT, antibody-drug conjugates, and locoregional therapies (Y-90 radioembolization, TACE) combined with systemic agents. Targeted therapy trials for specific mutations (FGFR, MET amplification) are also active.

Does my liver function (Child-Pugh score) affect HCC trial eligibility?

Yes — Child-Pugh score is one of the most important eligibility criteria for liver cancer trials. Most trials require Child-Pugh A (well-compensated liver function). Some trials accept Child-Pugh B7, but Child-Pugh B8 or higher and Child-Pugh C are typically excluded. If you have cirrhosis or significant liver disease, discuss your liver function score with your hepatologist or oncologist before pursuing trials.

Can I join a liver cancer trial if I have hepatitis B or C?

Having hepatitis B or C does not automatically exclude you, but treatment history matters. Many trials require that hepatitis B be controlled with antiviral therapy. Hepatitis C treatment does not typically affect eligibility. Active, uncontrolled viral hepatitis may be an exclusion criterion. The trial protocol will specify requirements for viral hepatitis management.

Are there trials for bile duct cancer (cholangiocarcinoma) as well as liver cancer?

Cholangiocarcinoma (bile duct cancer) and hepatocellular carcinoma (HCC) are different diseases. Cholangiocarcinoma trials — especially those targeting IDH1 mutations (ivosidenib) and FGFR2 fusions (pemigatinib, infigratinib) — are active and expanding. When you search on Trialify, selecting the correct diagnosis will ensure you see the right trials.

What is TACE, and can I join a liver cancer trial while receiving it?

Transarterial chemoembolization (TACE) is a locoregional treatment that delivers chemotherapy directly to liver tumors via blood vessels. Several trials combine TACE with systemic immunotherapy or targeted agents. Eligibility depends on how recently you received TACE (wash-out periods are common) and whether your liver lesions are still measurable after treatment.

Explore Other Cancer Trial Guides

• Pancreatic Cancer — Pancreatic cancer trials are at the forefront of KRAS inhibitor research, mRNA vaccines, and combination immunotherapy. Participating in a trial may give access to treatments not yet available to the general public.
• Colorectal Cancer — Colorectal cancer trials are evaluating immunotherapy for MSI-H tumors, KRAS and BRAF targeted therapies, and novel combinations for metastatic disease. Many trials enroll both colon and rectal cancer patients.
• Kidney Cancer — Kidney cancer trials are evaluating immunotherapy combinations, HIF-2α inhibitors like belzutifan, and novel TKI regimens for clear cell and non-clear cell renal cell carcinoma.
• Bladder Cancer — Bladder cancer trials are evaluating checkpoint immunotherapy, enfortumab vedotin-based combinations, and FGFR inhibitors for both non-muscle-invasive and muscle-invasive disease.